Other
Foreign
Vertex Pharmaceuticals Foreign remained flat by 0.0% to $121.45M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 56.8%, from $77.45M to $121.45M. Over 2 years (FY 2023 to FY 2025), Foreign shows an upward trend with a 17.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Higher values indicate higher tax obligations in international markets.
Detailed definition
The portion of the total income tax provision that is payable to foreign governments for the current reporting period. T...
Peer comparison
Standard tax disclosure for multinational corporations.
Metric ID:
other_current_foreign_tax_expense_benefitHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $350.10M | $309.80M | $485.80M |
| YoY Change | — | -11.5% | +56.8% |
Range$309.80M – $485.80M
CAGR+17.8%
Avg YoY Growth+22.6%
Median YoY Growth+22.6%
Foreign at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's foreign?
- Vertex Pharmaceuticals (VRTX) reported foreign of $121.45M in Q4 2025.
- How has Vertex Pharmaceuticals's foreign changed year-over-year?
- Vertex Pharmaceuticals's foreign increased by 56.8% year-over-year, from $77.45M to $121.45M.
- What is the long-term trend for Vertex Pharmaceuticals's foreign?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's foreign has grown at a 17.8% compound annual growth rate (CAGR), from $350.10M to $485.80M.
- What does foreign mean?
- Current income tax expense owed to foreign jurisdictions.